These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32001495)

  • 21. Efficacy of Live Attenuated Herpes Zoster Vaccine in Patients With Inflammatory Bowel Diseases.
    Khan N; Trivedi C; Kavani H; Medvedeva E; Lewis J; Yang YX
    Clin Gastroenterol Hepatol; 2019 Jun; 17(7):1341-1347. PubMed ID: 30326303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: a population-based study.
    Andrews N; Stowe J; Kuyumdzhieva G; Sile B; Yonova I; de Lusignan S; Ramsay M; Amirthalingam G
    BMJ Open; 2020 Jul; 10(7):e037458. PubMed ID: 32641364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial.
    Beals CR; Railkar RA; Schaeffer AK; Levin Y; Kochba E; Meyer BK; Evans RK; Sheldon EA; Lasseter K; Lang N; Weinberg A; Canniff J; Levin MJ
    Lancet Infect Dis; 2016 Aug; 16(8):915-22. PubMed ID: 27061887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Gomes Silva BN; Torloni MR; Soares BG
    Cochrane Database Syst Rev; 2012 Oct; 10():CD008858. PubMed ID: 23076951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial.
    Mok CC; Chan KH; Ho LY; Fung YF; Fung WF; Woo PCY
    Ann Rheum Dis; 2019 Dec; 78(12):1663-1668. PubMed ID: 31530556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of herpes zoster vaccination in an older United Kingdom population.
    Walker JL; Andrews NJ; Amirthalingam G; Forbes H; Langan SM; Thomas SL
    Vaccine; 2018 Apr; 36(17):2371-2377. PubMed ID: 29555217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Shingrix for Herpes Zoster: A Review.
    Shah RA; Limmer AL; Nwannunu CE; Patel RR; Mui UN; Tyring SK
    Skin Therapy Lett; 2019 Jul; 24(4):5-7. PubMed ID: 31339679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009.
    Weinmann S; Chun C; Schmid DS; Roberts M; Vandermeer M; Riedlinger K; Bialek SR; Marin M
    J Infect Dis; 2013 Dec; 208(11):1859-68. PubMed ID: 23922376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zoster vaccine: current status and future prospects.
    Oxman MN
    Clin Infect Dis; 2010 Jul; 51(2):197-213. PubMed ID: 20550454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older.
    Izurieta HS; Wernecke M; Kelman J; Wong S; Forshee R; Pratt D; Lu Y; Sun Q; Jankosky C; Krause P; Worrall C; MaCurdy T; Harpaz R
    Clin Infect Dis; 2017 Mar; 64(6):785-793. PubMed ID: 28362955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.
    Mullane KM; Morrison VA; Camacho LH; Arvin A; McNeil SA; Durrand J; Campbell B; Su SC; Chan ISF; Parrino J; Kaplan SS; Popmihajlov Z; Annunziato PW;
    Lancet Infect Dis; 2019 Sep; 19(9):1001-1012. PubMed ID: 31399378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study.
    Amirthalingam G; Andrews N; Keel P; Mullett D; Correa A; de Lusignan S; Ramsay M
    Lancet Public Health; 2018 Feb; 3(2):e82-e90. PubMed ID: 29276017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
    Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
    Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Varicella-zoster virus vaccination under the exogenous boosting hypothesis: two ethical perspectives.
    Luyten J; Ogunjimi B; Beutels P
    Vaccine; 2014 Dec; 32(52):7175-8. PubMed ID: 25454883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Aoki T; Koh K; Kawano Y; Mori M; Arakawa Y; Kato M; Hanada R
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):771-775. PubMed ID: 26748161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial.
    Curtis JR; Cofield SS; Bridges SL; Bassler J; Deodhar A; Ford TL; Huffstutter J; Jankeel A; Kivitz A; Kamal S; Lindsey S; Messaoudi I; Mendoza N; Michaud K; Mikuls TR; Ridley D; Shergy W; Siegel SAR; Winthrop KL
    Ann Intern Med; 2021 Nov; 174(11):1510-1518. PubMed ID: 34570596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
    J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial.
    Hata A; Inoue F; Hamamoto Y; Yamasaki M; Fujikawa J; Kawahara H; Kawasaki Y; Honjo S; Koshiyama H; Moriishi E; Mori Y; Ohkubo T
    Diabet Med; 2016 Aug; 33(8):1094-101. PubMed ID: 26605507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.